Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 7
2003 19
2004 17
2005 22
2006 14
2007 38
2008 48
2009 58
2010 70
2011 85
2012 76
2013 77
2014 81
2015 96
2016 83
2017 67
2018 57
2019 50
2020 52
2021 36
2022 41
2023 28
2024 43
2025 34
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,045 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Jones PH, et al. Am J Cardiol. 2003 Jul 15;92(2):152-60. doi: 10.1016/s0002-9149(03)00530-7. Am J Cardiol. 2003. PMID: 12860216 Clinical Trial.
Mean percent changes in high-density lipoprotein cholesterol in the rosuvastatin groups were +7.7% to +9.6% compared with +2.1% to +6.8% in all other groups. ...Adult Treatment Panel III LDL cholesterol goals were achieved by 82% to 89% of patients treated with rosuvast …
Mean percent changes in high-density lipoprotein cholesterol in the rosuvastatin groups were +7.7% to +9.6% compared with +2.1% to +6 …
Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial.
Hong SJ, Lee YJ, Kang WC, Hong BK, Lee JY, Lee JB, Yang TH, Yoon J, Lee SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; LODESTAR investigators. Hong SJ, et al. Cardiovasc Diabetol. 2024 Aug 7;23(1):287. doi: 10.1186/s12933-024-02386-w. Cardiovasc Diabetol. 2024. PMID: 39113067 Free PMC article. Clinical Trial.
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This study aimed to evaluate the risk of NODM in patients w …
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-int …
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC. Moon JS, et al. Diabetes Metab J. 2023 Nov;47(6):818-825. doi: 10.4093/dmj.2023.0171. Epub 2023 Nov 24. Diabetes Metab J. 2023. PMID: 38043782 Free PMC article. Clinical Trial.
BACKGRUOUND: To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM). ...The prim …
BACKGRUOUND: To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensit …
Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.
Joseph P, Glynn R, Lonn E, Ramasundarahettige C, Eikelboom J, MacFadyen J, Ridker P, Yusuf S. Joseph P, et al. Cardiovasc Res. 2022 Feb 21;118(3):897-903. doi: 10.1093/cvr/cvab078. Cardiovasc Res. 2022. PMID: 33705531 Free PMC article.
There were 139 VTE events. In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75). ...CONCLUSION: Rosuvastatin is associated with a 47% proportional reduction in the risk of VTE, …
There were 139 VTE events. In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE ( …
Lipid-lowering efficacy of rosuvastatin.
Adams SP, Sekhon SS, Wright JM. Adams SP, et al. Cochrane Database Syst Rev. 2014 Nov 21;2014(11):CD010254. doi: 10.1002/14651858.CD010254.pub2. Cochrane Database Syst Rev. 2014. PMID: 25415541 Free PMC article.
BACKGROUND: Rosuvastatin is one of the most potent statins and is currently widely prescribed. It is therefore important to know the dose-related magnitude of effect of rosuvastatin on blood lipids. ...Log dose-response data over doses of 1 to 80 mg, revealed strong …
BACKGROUND: Rosuvastatin is one of the most potent statins and is currently widely prescribed. It is therefore important to know the …
Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis.
Liu L, Deng Y, Li L, Yang X, Yin Z, Lai Y. Liu L, et al. PLoS One. 2024 Nov 13;19(11):e0310696. doi: 10.1371/journal.pone.0310696. eCollection 2024. PLoS One. 2024. PMID: 39536001 Free PMC article.
OBJECTIVE: To systematically review the efficacy and safety of Moderate-intensity Rosuvastatin Plus Ezetimibe compared with High-intensity Rosuvastatin in treating Composite Cardiovascular Events. ...The findings indicated that moderate-intensity statin combination …
OBJECTIVE: To systematically review the efficacy and safety of Moderate-intensity Rosuvastatin Plus Ezetimibe compared with High-inte …
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.
Singh H, Kaur S, Kaushal P, Sharma J, Singla M. Singh H, et al. Expert Rev Clin Pharmacol. 2024 Dec;17(12):1173-1181. doi: 10.1080/17512433.2024.2433603. Epub 2024 Nov 25. Expert Rev Clin Pharmacol. 2024. PMID: 39587804
BACKGROUND: Statins are linked to the risk of new-onset diabetes mellitus (NODM). While atorvastatin and rosuvastatin are often associated with NODM, pitavastatin may carry a lower risk. This systematic review and meta-analysis (SRMA) evaluated the impact of pitavastatin o …
BACKGROUND: Statins are linked to the risk of new-onset diabetes mellitus (NODM). While atorvastatin and rosuvastatin are often assoc …
Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial.
Ji X, Xia J, Zhang H, Ren C, Ma G, Fu S, Zhang J, Chen Y, Han X, Zhang J, Fang Z, Yang B, Yang B, Huang W, Yin G, Qi H, Gong H, Wang D, Hao L, Zhao X, Pei Z, Wang P, Li X, Lin L, Li D, Li Z, Zhang L, Yin B, Cheng Y, You Z, Sheng J, Wu J, Chen L, Fan Z, Zhao W, Zhao S. Ji X, et al. Lipids Health Dis. 2025 Jul 22;24(1):249. doi: 10.1186/s12944-025-02670-y. Lipids Health Dis. 2025. PMID: 40696391 Free PMC article. Clinical Trial.
Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to week (W)12 was greater in the rosuvastatin/ezetimibe 10/10 mg group vs. rosuvastatin 10 mg group [least-squares means (LSmean): -51.48% vs. -42.47%], rosuvastatin/ezetimibe 5/10 …
Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to week (W)12 was greater in the rosuvastatin/ezetimib …
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.
Kang Y, Park JM, Lee SH. Kang Y, et al. Yonsei Med J. 2024 Jan;65(1):19-26. doi: 10.3349/ymj.2023.0285. Yonsei Med J. 2024. PMID: 38154476 Free PMC article.
We compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. MATERIALS AND METHODS: A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December …
We compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. MATER …
Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis.
Sayehmiri K, Shohani M, Qavam S, Tavan H. Sayehmiri K, et al. Life Sci. 2025 Jun 1;370:123576. doi: 10.1016/j.lfs.2025.123576. Epub 2025 Mar 24. Life Sci. 2025. PMID: 40132725
The present study aimed to compare the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL using a systematic review and meta-analysis method. ...SIGNIFICANCE: According to research results, Rosuvastatin was better than Atorvastatin and decr …
The present study aimed to compare the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL using a systemati …
1,045 results